4.7 Article

Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1

Journal

FOOD AND CHEMICAL TOXICOLOGY
Volume 50, Issue 9, Pages 3025-3031

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.fct.2012.06.006

Keywords

Naringenin; Vascular smooth muscle cells; Proliferation; Migration; Heme oxygenase-1

Funding

  1. National Basic Research Program of China (973 Program) [2012CB947600]
  2. Program for New Century Excellent Talents in University by the Chinese Ministry of Education (NCET)
  3. National Natural Science Foundation of China [31171137]
  4. Key Project of Chinese Ministry of Education [211062]
  5. Research Fund for the Doctoral Program of Higher Education of China [20103207110007]
  6. Fok Ying Tong Education Foundation [121022]
  7. Major Program of Educational Commission of Jiangsu Province [09KJA180004]
  8. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)

Ask authors/readers for more resources

Vascular smooth muscle cell (VSMC) proliferation and migration, which is triggered by various inflammatory stimuli, contributes importantly to the pathogenesis of atherosclerosis and restenosis. Naringenin is a citrus flavonoid with both lipid-lowering and insulin-like properties. Here, we investigated whether naringenin affects TNF-alpha-induced VSMC proliferation and migration and if so, whether heme oxygenase-1 (HO-1) is involved. Rat VSMCs were treated with naringenin alone or in combination of TNF-alpha stimulation. We found that naringenin induced HO-1 mRNA and protein levels, as well as its activity, in VSMCs. Naringenin inhibited TNF-alpha-induced VSMC proliferation and migration in a dose-dependent manner. Mechanistic study demonstrated that naringenin prevented ERK/MAPK and Akt phosphorylation while left p38 MAPK and JNK unchanged. Naringenin also blocked the increase of ROS generation induced by TNF-alpha. More importantly, the specific HO-1 inhibitor ZnPP IX or HO-1 siRNA partially abolished the beneficial effects of naringenin on VSMCs. These results suggest that naringenin may serve as a novel drug in the treatment of these pathologies by inducing HO-1 expression/activity and subsequently decreasing VSMC proliferation and migration. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available